CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
EA1141 ECOG-ACRIN Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts Cancer Prevention and Control CIRB
EA1151 ECOG-ACRIN Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Cancer Prevention and Control CIRB
EA1181 ECOG-ACRIN (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Adult CIRB - Late Phase Emphasis
EA1183 ECOG-ACRIN FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE Adult CIRB - Late Phase Emphasis
EA1211 ECOG-ACRIN Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial Adult CIRB - Late Phase Emphasis
EA2131 ECOG-ACRIN A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine with or without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas Adult CIRB - Early Phase Emphasis
EA2142 ECOG-ACRIN Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms Adult CIRB - Early Phase Emphasis
EA2161 ECOG-ACRIN A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) Adult CIRB - Late Phase Emphasis
EA2165 ECOG-ACRIN A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Adult CIRB - Late Phase Emphasis
EA2174 ECOG-ACRIN A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Adult CIRB - Late Phase Emphasis